Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACET | US
-0.02
-1.35%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
30/08/2024
1.46
1.48
1.51
1.46
Adicet Bio Inc. a clinical stage biotechnology company discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting facilitate innate and adaptive anti-tumor immune response and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001 which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002 which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925 a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio Inc. is based in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
74.8%1 month
70.4%3 months
75.0%6 months
78.5%-
-
0.52
0.08
0.07
-1.21
2.14
0.82
-121.50M
120.31M
120.31M
-
-
-
-100.00
-57.91
4.97
6.57
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.25
Range1M
0.38
Range3M
0.65
Rel. volume
0.47
Price X volume
348.90K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Zomedica Pharmaceuticals Corp | ZOM | Drug Manufacturers-Specialty & Generic | 0.1289 | 128.64M | 1.90% | n/a | 1.10% |
Veru Inc | VERU | Drug Manufacturers-Specialty & Generic | 0.8184 | 119.80M | 0.42% | n/a | 36.36% |
Assertio Therapeutics Inc | ASRT | Drug Manufacturers-Specialty & Generic | 1.18 | 112.50M | 1.72% | n/a | 30.76% |
INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 2.27 | 103.45M | 1.79% | n/a | 41.98% |
Karyopharm Therapeutics Inc | KPTI | Drug Manufacturers-Specialty & Generic | 0.7602 | 94.78M | -1.38% | n/a | -148.05% |
Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 9.245 | 93.25M | 2.15% | n/a | 3.08% |
Relmada Therapeutics Inc | RLMD | Drug Manufacturers-Specialty & Generic | 2.8 | 84.49M | 6.06% | n/a | 0.00% |
Universe Pharmaceuticals INC | UPC | Drug Manufacturers-Specialty & Generic | 3.25 | 76.85M | -0.61% | n/a | 13.87% |
Silver Spike Investment Corp. Common Stock | SSIC | Drug Manufacturers-Specialty & Generic | 11.46 | 71.22M | -0.17% | 12.73 | 0.00% |
Eagle Pharmaceuticals Inc | EGRX | Drug Manufacturers-Specialty & Generic | 5.14 | 66.61M | -1.91% | 5.00 | 27.85% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Unifi Inc | UFI | Textile Manufacturing | 6.83 | 124.66M | -2.84% | n/a | 52.56% |
Culp Inc | CULP | Textile Manufacturing | 5.02 | 62.60M | 0.20% | n/a | 11.29% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
The Dixie Group Inc | DXYN | Textile Manufacturing | 0.76 | 11.69M | 7.80% | n/a | 422.08% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.97% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 2.11M | -7.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.21 | - | Cheaper |
Ent. to Revenue | 2.14 | - | Cheaper |
PE Ratio | - | 28.13 | - |
Price to Book | 0.52 | 11.07 | Cheaper |
Dividend Yield | - | - | - |
Std. Deviation (3M) | 75.01 | - | Par |
Debt to Equity | 0.08 | -0.91 | Expensive |
Debt to Assets | 0.07 | 0.45 | Cheaper |
Market Cap | 120.31M | - | Emerging |